Abzena plc (LON:ABZA) has noted US pharma Gilead Sciences Inc's (Nasdaq:GILD) decision to end the Phase II/III clinical study of GS-5745 in patients with ulcerative colitis.
Abzena added the termination affects only one indication out of five and Gilead has confirmed that its Phase II and III studies of GS-5745 in patients with gastric cancer, Crohn's disease, rheumatoid arthritis and cystic fibrosis will continue as planned.
The GS-5745 antibody includes Abzena's Composite Human Antibody technology and is one of 12 of its products currently in clinical development through over 40 licence and option agreements.
Gilead said interim analysis of the unblinded efficacy and safety data contained insufficient evidence of a treatment benefit in the group of study patients randomized to receive either one of two doses of GS-5745.